- Email: [email protected]
572 Chemo-hormonotherapy of advanced breast cancer
203s 572
CHEMO-HORMONOTHERAPY OF ADVANCED BREAST CANCER, B.Massidda, A.Farris; V.Mascia, L.Fratif M.L.CkiWJ:
University of Cagliari,Sassari", Roma+- Itc.Zy. A total of 88 pts.were entered in this trial of chemo-hormonotherapyin advanced breast cant r.Chemotherapy alone regimen:VCR lmg i.v. day 1, ADM 50 mg/m*i.v. day 1, CTX 100 mgfm1p.o. day 1-8,has been compared with chemotherapy plus medroxyprogesterone acetate(HD-MYF'A 500 mg i.m.for 15 days then twice weekly until progression)or chemotherapy plus tamoxifen(TAM 30 mg daily). The observed response rates,median duration,survival(months),at 48 months of follow-up, were (UICC criteria) :
evaZ.pts.
CR+PR>SO%
No ChangeResponsMat.
Survival
VAC+MPA 29 47.2%(15.7+31.5) 21.0% 15.0 22.5 VAC+TAM 31 41.9%(12.9+29.0) 32.2% 11.0 21.0 VAC 28 45.0%(10.0+35.0) 15.0% 12.0 24.0 Regimens were well tolerated.VAC+MFAand VAC+TAM appeared to be equivalent to induce global remissions.Treatmentswith a combination of chemotherapy and hormonotherapy represent a more aggressive strategy apparently achiving apparently higher response rates(partia1 remissions and stable disease)but it cannot be concluded that it may be considered the routinely recommended treatment for every pts.Questions concerning quality of life, time to progression, survival and possibly drugs interferences during the simultaneous treatment will be discussed.
CHEMO-HORMONOTHERAPY OF ADVANCED BREAST CANCER, B.Massidda, A.Farris; V.Mascia, L.Fratif M.L.CkiWJ:
University of Cagliari,Sassari", Roma+- Itc.Zy. A total of 88 pts.were entered in this trial of chemo-hormonotherapyin advanced breast cant r.Chemotherapy alone regimen:VCR lmg i.v. day 1, ADM 50 mg/m*i.v. day 1, CTX 100 mgfm1p.o. day 1-8,has been compared with chemotherapy plus medroxyprogesterone acetate(HD-MYF'A 500 mg i.m.for 15 days then twice weekly until progression)or chemotherapy plus tamoxifen(TAM 30 mg daily). The observed response rates,median duration,survival(months),at 48 months of follow-up, were (UICC criteria) :
evaZ.pts.
CR+PR>SO%
No ChangeResponsMat.
Survival
VAC+MPA 29 47.2%(15.7+31.5) 21.0% 15.0 22.5 VAC+TAM 31 41.9%(12.9+29.0) 32.2% 11.0 21.0 VAC 28 45.0%(10.0+35.0) 15.0% 12.0 24.0 Regimens were well tolerated.VAC+MFAand VAC+TAM appeared to be equivalent to induce global remissions.Treatmentswith a combination of chemotherapy and hormonotherapy represent a more aggressive strategy apparently achiving apparently higher response rates(partia1 remissions and stable disease)but it cannot be concluded that it may be considered the routinely recommended treatment for every pts.Questions concerning quality of life, time to progression, survival and possibly drugs interferences during the simultaneous treatment will be discussed.